Actively Recruiting
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
Led by Peking University People's Hospital · Updated on 2025-04-24
20
Participants Needed
2
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the use of teclistamab in systemic AL amyloidosis and answer whether teclistamab can improve the rate of complete hematological response. This is a single-arm, multi-center, prospective study. Participants will receive the single drug teclistamab, which the investigator deems the best choice.
CONDITIONS
Official Title
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of systemic AL amyloidosis
- Prior treatment with daratumumab and bortezomib without achieving at least one organ response or complete hematological response
- Life expectancy greater than 12 weeks
- Hemoglobin level 70 g/L or higher
- Blood oxygen saturation greater than 90%
- Total bilirubin less than or equal to 3 times the upper limit of normal
- Aspartate aminotransferase and alanine aminotransferase less than or equal to 3 times the upper limit of normal
- Provided informed consent after explanation and understanding
You will not qualify if you...
- Active multiple myeloma or active lymphoplasmacytic lymphoma
- Presence of other advanced malignant tumors with systemic metastasis
- Severe or persistent infections that cannot be controlled effectively
- Severe autoimmune diseases or immunodeficiency disorders
- Active hepatitis B or hepatitis C infection
- HIV or syphilis infection
- Any condition that increases risk for the participant or may affect study results as judged by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Peking University Peoples Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
2
Fuxing Hospital affiliated to Capital Medical University
Beijing, China
Actively Recruiting
Research Team
Y
Yang Dr, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here